A deep learning model based on whole slide images to predict disease-free survival in cutaneous melanoma patients.


Journal

Scientific reports
ISSN: 2045-2322
Titre abrégé: Sci Rep
Pays: England
ID NLM: 101563288

Informations de publication

Date de publication:
27 11 2022
Historique:
received: 14 09 2022
accepted: 14 11 2022
entrez: 27 11 2022
pubmed: 28 11 2022
medline: 30 11 2022
Statut: epublish

Résumé

The application of deep learning on whole-slide histological images (WSIs) can reveal insights for clinical and basic tumor science investigations. Finding quantitative imaging biomarkers from WSIs directly for the prediction of disease-free survival (DFS) in stage I-III melanoma patients is crucial to optimize patient management. In this study, we designed a deep learning-based model with the aim of learning prognostic biomarkers from WSIs to predict 1-year DFS in cutaneous melanoma patients. First, WSIs referred to a cohort of 43 patients (31 DF cases, 12 non-DF cases) from the Clinical Proteomic Tumor Analysis Consortium Cutaneous Melanoma (CPTAC-CM) public database were firstly annotated by our expert pathologists and then automatically split into crops, which were later employed to train and validate the proposed model using a fivefold cross-validation scheme for 5 rounds. Then, the model was further validated on WSIs related to an independent test, i.e. a validation cohort of 11 melanoma patients (8 DF cases, 3 non-DF cases), whose data were collected from Istituto Tumori 'Giovanni Paolo II' in Bari, Italy. The quantitative imaging biomarkers extracted by the proposed model showed prognostic power, achieving a median AUC value of 69.5% and a median accuracy of 72.7% on the public cohort of patients. These results remained comparable on the validation cohort of patients with an AUC value of 66.7% and an accuracy value of 72.7%, respectively. This work is contributing to the recently undertaken investigation on how treat features extracted from raw WSIs to fulfil prognostic tasks involving melanoma patients. The promising results make this study as a valuable basis for future research investigation on wider cohorts of patients referred to our Institute.

Identifiants

pubmed: 36437296
doi: 10.1038/s41598-022-24315-1
pii: 10.1038/s41598-022-24315-1
pmc: PMC9701687
doi:

Types de publication

Journal Article Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

20366

Subventions

Organisme : Ministero della Salute
ID : RC2022

Informations de copyright

© 2022. The Author(s).

Références

Eur J Cancer. 2021 Sep;154:227-234
pubmed: 34298373
J Digit Imaging. 2013 Dec;26(6):1045-57
pubmed: 23884657
Nature. 2015 May 28;521(7553):436-44
pubmed: 26017442
J Surg Oncol. 2019 Jan;119(2):175-186
pubmed: 30548543
Expert Opin Ther Targets. 2012 Apr;16 Suppl 2:S61-70
pubmed: 22443134
Sci Rep. 2017 Dec 4;7(1):16878
pubmed: 29203879
J Transl Med. 2019 Aug 14;17(1):266
pubmed: 31412885
Transl Oncol. 2021 Jan;14(1):100921
pubmed: 33129113
J Am Acad Dermatol. 2015 May;72(5):780-5.e3
pubmed: 25748297
World J Surg Oncol. 2019 Jul 25;17(1):129
pubmed: 31345228
N Engl J Med. 2011 Jun 30;364(26):2517-26
pubmed: 21639810
J Clin Pathol. 2019 Apr;72(4):265-270
pubmed: 30275100
Lymphat Res Biol. 2017 Jun;15(2):146-152
pubmed: 28617648
ESMO Open. 2021 Apr;6(2):100064
pubmed: 33711672
Neurol Clin Neurophysiol. 2004 Nov 30;2004:37
pubmed: 16012598
Eur J Cancer. 2019 Jul;115:79-83
pubmed: 31129383
Cancers (Basel). 2021 May 11;13(10):
pubmed: 34064923
Cancer. 1950 Jan;3(1):32-5
pubmed: 15405679
EJC Suppl. 2013 Sep;11(2):81-91
pubmed: 26217116
Clin Cancer Res. 2020 Mar 1;26(5):1126-1134
pubmed: 31636101
Sensors (Basel). 2016 Jan 18;16(1):
pubmed: 26797612
Eur J Cancer. 2019 Sep;118:91-96
pubmed: 31325876
Sci Rep. 2021 Jul 8;11(1):14123
pubmed: 34238968
JAMA. 2018 Oct 23;320(16):1702-1703
pubmed: 30286224
World J Surg Oncol. 2020 Jun 16;18(1):130
pubmed: 32546168
J Cutan Pathol. 1992 Oct;19(5):390-7
pubmed: 1474192
Am J Orthod Dentofacial Orthop. 2016 Nov;150(5):898-899
pubmed: 27871717
J Invest Dermatol. 2014 Aug;134(8):2202-2211
pubmed: 24522433
Am J Manag Care. 2019 Mar 1;25(3):e66-e70
pubmed: 30875173
J Invest Dermatol. 2018 Jul;138(7):1529-1538
pubmed: 29428356
Virchows Arch A Pathol Anat Histopathol. 1987;410(4):355-61
pubmed: 3101284
Artif Intell Med. 2017 Jan;75:51-63
pubmed: 28363456

Auteurs

Maria Colomba Comes (MC)

I.R.C.C.S. Istituto Tumori "Giovanni Paolo II", Viale Orazio Flacco 65, 70124, Bari, Italy.

Livia Fucci (L)

I.R.C.C.S. Istituto Tumori "Giovanni Paolo II", Viale Orazio Flacco 65, 70124, Bari, Italy.

Fabio Mele (F)

I.R.C.C.S. Istituto Tumori "Giovanni Paolo II", Viale Orazio Flacco 65, 70124, Bari, Italy.

Samantha Bove (S)

I.R.C.C.S. Istituto Tumori "Giovanni Paolo II", Viale Orazio Flacco 65, 70124, Bari, Italy. s.bove@oncologico.bari.it.

Cristian Cristofaro (C)

I.R.C.C.S. Istituto Tumori "Giovanni Paolo II", Viale Orazio Flacco 65, 70124, Bari, Italy.

Ivana De Risi (I)

I.R.C.C.S. Istituto Tumori "Giovanni Paolo II", Viale Orazio Flacco 65, 70124, Bari, Italy.

Annarita Fanizzi (A)

I.R.C.C.S. Istituto Tumori "Giovanni Paolo II", Viale Orazio Flacco 65, 70124, Bari, Italy. a.fanizzi@oncologico.bari.it.

Martina Milella (M)

I.R.C.C.S. Istituto Tumori "Giovanni Paolo II", Viale Orazio Flacco 65, 70124, Bari, Italy.

Sabino Strippoli (S)

I.R.C.C.S. Istituto Tumori "Giovanni Paolo II", Viale Orazio Flacco 65, 70124, Bari, Italy.

Alfredo Zito (A)

I.R.C.C.S. Istituto Tumori "Giovanni Paolo II", Viale Orazio Flacco 65, 70124, Bari, Italy.

Michele Guida (M)

I.R.C.C.S. Istituto Tumori "Giovanni Paolo II", Viale Orazio Flacco 65, 70124, Bari, Italy.

Raffaella Massafra (R)

I.R.C.C.S. Istituto Tumori "Giovanni Paolo II", Viale Orazio Flacco 65, 70124, Bari, Italy.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH